FORTHCOMING EVENTS

BIO 2023: A Price Control Odyssey : The Inflation Reduction Act’s Effects on the Innovation Ecosystem

The Inflation Reduction Act (IRA) contains some of the most significant changes to prescription drug pricing, reimbursement, and access since the Affordable Care Act was enacted over a decade ago. A new study by Vital Transformation, a health care economics consultancy, looks at the economic impacts on the innovation ecosystem and access to new therapies, with a particular focus on drug discovery and rare disease. As the federal government implements the price control provisions of the IRA, biotech hubs like Boston, Massachusetts- home to a significant number of established and emerging biotech companies- will bear the brunt of those impacts as they manage R&D pipelines.

Panelists, amongst whom Duane Schulthess, CEO of Vital Transformation, will discuss the studies findings, and look at the chilling effects on venture funding, orphan drug impacts, and reduced treatments reaching patients.

Wednesday, June 7, 2023, 1:45 PM - 2:45 PM (EDT) - Session Room 254B (click Read More for the session link)

And if you can't attend the session but are keen to discuss this topic, come and visit the Vital Transformation booth at the BIO Exhibition, we're in booth 1180!

Nashville.Bio Putting the REAL into RWE

Podcast with Nashville.Bio - Putting the REAL into RWE Nashville Biosciences and Vital Transformation are collaborating on a ground-breaking project to measure the impact of CAR-T on the total cost of treating cancer by harnessing RWE. The CEO of Nashville [...]

REPORTS

Better Science, Better Health
27-28th October 2015, US Congress, Washington DC
Resources now available

Reports, videos and more...

Universal health: Investing in Health and Wellbeing for All
June 29th-30th, RIGA
Resources now available

Videos and downloads

Webinar: MAPPs – New Tools for Decision Making
April 14th, 2015, 2-3pm CEST
Resources now available

Read the article

RWE and Health Data in the EU: viable public policy vs. political overreach
February 7, 2016 - by Duane Schulhtess, Managing Director, Vital Transformation

Read the article

RECENT EVENTS

WEBINAR: GetReal – Identifying the Operational challenges of Performing RWE Research (WP3)


October 6, 2016
WP 3 has two main goals. Identify operational challenges when implementing RWE research to investigate the effectiveness of medicines, earlier in the medicine development process. Second, to estimate the impact of these challenges on the ability to generate the RWE originally aimed for and the feasibility of the research and provide practical solutions to help address them. This webinar will update you on these goals.

ARCHIVE

DIA Bioventure Day 2017 – Crown Plaza Glasgow, UK


March 28th, 2017
DIA is excited to convene its 1st BioVenture Day, in a unique format with participation of a very broad set of senior Health Care stakeholders.You will be able to explore whether the current BioVenture paradigm is delivering return for patients, investors, and the Health Care system.

EMIF: E-managing the Future of Health Data


March 16th-17th, Budapest
Harnessing electronic health records and real world evidence to create new therapies more efficiently is quickly becoming a reality. How do we maximize the benefits offered by harnessing available health data while solving issues around its reuse and work with regulators to provide the right evidence?.

Supported by:

Webinar: MAPPs – New Tools for Decision Making


April 14th, 2:00 pm - 3:00 pm CEST
What is the current status of MAPPs in Europe and the US?

Featuring:

  • Luca Pani, Director General, Italian Medicines Agency
  • Gigi Hirsch, Executive Director, CBI and Program Director, NEWDIGS, MIT, USA
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline, UK
  • Duane Schulthess, Managing Director, Vital Transformation (moderator)

DIA EuroMeeting 2015| Palais des Congrès | Paris


April 13th -15th, 2015 - Theme 9 - Big Data, Mobile Health
Harnessing Big Data to make better, quicker medical decisions is a logical development. However, this demands a delicate balance between individual patient rights and the wider public good. This theme explores how to reconcile these issues to maximise the benefits offered by harnessing available health data. How can Big Data improve patient outcomes and accelerate clinical development? What are the implications of data ownership, and what will be the role of social media in healthcare?

Digital Health: Catapulting Personalised Medicine Forward

November 27th, 2014 - Connected Digital Economy Catapult, London

This round table will feature demonstrations of how next-generation technologies and social media will integrate with public health, thus facilitating the burgeoning market for personalised medicines. The session will include disruptive start-ups and technology savvy practitioners finding common ground in the desire to bring stratified medicines to patients.

This event is organised in collaboration with:

logoFPM CDE_LG_Colour_CMYK-3 DCC-Wordmark-Black-RGB

Real World Evidence in Adaptive Clinical Trial Design

September 17th, 2014, Brussels, 9.00-14.00 CET

What does Europe need to do to make this technology stew of mobile apps, eHealth platforms, and national heatlhcare systems work together in seamless harmony?

This round table is organised in partnership with:

efpiasq logoFPM

Sustainable health systems for inclusive growth in Europe

19-20 November, Vilnius: The main aim of the annual Conference, which will be held under the auspices of the Lithuanian Presidency of the Council of the EU, is to identify the existing best evidence on fostering the development of sustainable health systems throughout the entire Europe.

A Roadmap for Sharing Clinical Trial Data

August 27th, 2013 Brussels

EFPIA and the Pharmaceutical Research and Manufacturers of America (PhRMA) have issued a joint proposal to enhance responsible clinical trial data sharing. What does this mean practically for research in Europe, and what are the best practices for implementation?